Article

Marijuana-like Substance Reduces Pain Without the Mental Fog

Effective pain relief from a marijuana-like substance may be possible, according to a the results of a recent study published in the Anesthesia & Analgesia journal.

Effective pain relief from a marijuana-like substance may be possible, according to a the results of a recent study published in the Anesthesia & Analgesia journal.

While marijuana has been proven to offer some patients pain relief there can be mental and physical side effects. A new synthetic cannabinoid compound has the potential to relieve pain without causing adverse effects in the central nervous system. The compound is called MDA19 and acts on a specific subtype of the cannabinoid receptor.

Through a series of experiments, the researchers found that two subtypes of the cannabinoid chemical receptor exist; CB1 is found in the brain, while CB2 is found in the peripheral immune system. The synthetic compound, MDA19, has a much stronger effect on the CB2 receptor, and, in humans, the compound demonstrated four times greater activity on the CB2 receptor than on the CB1 receptor.

The compound also demonstrated the ability to either block or activate the cannabinoid receptors. When the treatment was given to rats, it had reduced certain types of neuropathic pain without the behavioral effects commonly associated with marijuana.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.